Back to top

United Therapeutics Corporation (UTHR)

(Delayed Data from NSDQ)

$195.42 USD


+3.35 (1.74%)

Updated May 7, 2021 04:00 PM ET

After-Market: $195.57 +0.15 (0.08%) 6:32 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
5Strong Sell3.06%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 17% (210 out of 254)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

Silver Spring, MD-based United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use.

The company licensed certain exclusive rights to Adcirca from Lilly in November 2008. The company paid upfront fees of $150 million to Lilly for the exclusive rights to commercialize Adcirca for the treatment of ...

General Information

United Therapeutics Corporation



Phone: 301-608-9292

Fax: 301-608-9291



Industry Medical - Drugs
Sector Medical
Fiscal Year End December
Last Reported Quarter 3/31/2021
Next EPS Date 8/4/2021

EPS Information

Current Quarter EPS Consensus Estimate 2.86
Current Year EPS Consensus Estimate 12.06
Estimated Long-Term EPS Growth Rate NA
Next EPS Report Date 8/4/2021

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 192.07
52 Week High 212.62
52 Week Low 98.37
Beta 0.51
20 Day Moving Average 308,216.34
Target Price Consensus 220.38


% Price Change
4 Week -4.31
12 Week 13.30
YTD 26.54
% Price Change Relative to S&P 500
4 Week -6.69
12 Week 5.60
YTD 13.12
Share Information
Shares Outstanding (millions) 44.80
Market Capitalization (millions) 8,604.05
Short Ratio NA
Last Split Date 9/23/2009
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio 0.00
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E (F1) 15.92
Trailing 12 Months 21.22
PEG Ratio NA
EPS Growth
vs. Previous Year -80.45%
vs. Previous Quarter -72.15%
Sales Growth
vs. Previous Year 6.40%
vs. Previous Quarter -1.51%
Price Ratios
Price/Book 2.50
Price/Cash Flow 15.11
Price / Sales 5.71
3/31/21 12.45
12/31/20 16.19
9/30/20 15.48
3/31/21 9.18
12/31/20 11.92
9/30/20 11.31
Current Ratio
3/31/21 NA
12/31/20 6.70
9/30/20 7.22
Quick Ratio
3/31/21 NA
12/31/20 6.44
9/30/20 6.88
Operating Margin
3/31/21 26.92
12/31/20 34.71
9/30/20 33.25
Net Margin
3/31/21 26.92
12/31/20 34.71
9/30/20 33.25
Pre-Tax Margin
3/31/21 33.19
12/31/20 43.07
9/30/20 42.06
Book Value
3/31/21 NA
12/31/20 76.40
9/30/20 73.88
Inventory Turnover
3/31/21 1.22
12/31/20 1.21
9/30/20 1.13
3/31/21 NA
12/31/20 0.24
9/30/20 0.24
Debt to Capital
3/31/21 NA
12/31/20 19.07
9/30/20 19.59